A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)

What Was Tested

The trial (phase 4) is built around Tirzepatide for psoriasis and psoriatic arthritis.

The study will last up to 12 months.

It had 1 arm (groups): Tirzepatide (experimental).

Participants will continue to receive ixekizumab and take tirzepatide subcutaneously (SC) as per label.

The registry classes the interventions as drug.

Who Took Part

200 planned participants were the target.

It was open to people of any sex aged from 18 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Have a diagnosis of moderate-to-severe plaque PsO, as defined by a dermatologist or other experienced clinician treated PsO (for example, allergologist, nurse practitioner or physician assistant). Must have initiated treatment with ixekizumab for approximately 3 months (± 1 month) prior to decision to add tirzepatide. Must be able to initiate tirzepatide (Day 0) within 30 days of treatment decision (baseline/screening).

The full record lists 4 inclusion and 12 exclusion criteria; among the exclusions: have currently received ixekizumab for more than 4 months or less than 2 months; have had any exposure to tirzepatide or other glucagon-like peptide-1 receptor agonist (glp-1 ras), for example, dulaglutide, liraglutide, or semaglutide; are currently enrolled in any other clinical study.

How the Study Was Run

The set-up was single-group and open-label.

Being open-label, the Tirzepatide study did not mask who received what.

Everyone received the same intervention, so there was no separate comparison group inside the trial.

It started in 2025-03-19 with completion listed for 2028-05.

It ran at 39 sites in United States (39).

Its stated primary purpose is treatment.

What Was Measured

Primary outcome: Percentage of Participants Achieving Dermatology Life Quality Index (DLQI) (0,1) (time frame: 12 months).

It also tracked 7 secondary outcomes, for example Percentage of Participants Achieving Static Physician's Global Assessment (sPGA) (0,1), Percentage of Participants Achieving DLQI ≤5, Percentage of Participants Achieving Patient Global Assessment (PatGA) Score ≤2 and Mean Percent Change of Weight from Baseline.

What This Means in Plain Language

Put simply, this is a phase 4 trial of Tirzepatide in 200 people with psoriasis and psoriatic arthritis.

It is still recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Tirzepatide compound page, Psoriasis and psoriatic arthritis research.